GUO Jian-bo,HE Qing-yong,WANG Jie,et al.Study on Medication Rules of Compound TCM with National Patents for Treatment of Heart Failure[J].zhongguo zhongyiyao xinxi zazhi,2018,25(8):98-101.[doi:10.3969/j.issn.1005-5304.2018.08.022]
基于国家专利的中药复方治疗心力衰竭用药规律研究
- Title:
- Study on Medication Rules of Compound TCM with National Patents for Treatment of Heart Failure
- 文章编号:
- 1005-5304(2018)08-0098-04
- Keywords:
- heart failure; patents; syndrome; compatibility rules; compound TCM
- 分类号:
- R2-05;R259.416.1
- 文献标志码:
- A
- 摘要:
- 目的 通过分析心力衰竭中药复方专利的用药及配伍规律,为中药新药研发提供参考。方法 计算机检索国家知识产权局中国专利公布公告网站(http://epub.sipo.gov.cn/)中治疗心力衰竭的中药复方专利数据,采用中医传承辅助平台(V2.5)频次统计、关联规则、复杂网络、熵聚类等方法进行分析。结果 纳入2003年9月-2017年11月治疗心力衰竭的中药复方专利120项,涉及药物383味,最常见的主治证候为气虚血瘀水停证(41次,34.17%);常用药物为黄芪(62次,51.67%),常用药对为丹参-黄芪(31次,25.83%),常用角药为黄芪-茯苓-葶苈子(16次,13.33%);置信度较高的关联规则有“丹参,当归→黄芪”(0.933)、“党参,白术→黄芪”(0.900)、“人参,葶苈子→茯苓”(0.889);核心药物为黄芪、人参、丹参等;新处方有“桂枝、五加皮、大枣、枳实、天麻”“白术、桂枝、大枣、当归、赤芍”等。结论 临床研发心力衰竭中药新药时,应针对其常见主治证候,活用益气、温阳、活血、化瘀、利水、化痰、养阴药物,以提高临床功效。
- Abstract:
- Objective To provide references for research and development of new TCM by analyzing the medication and compatibility rules of compound TCM patents for treatment of heart failure. Methods All compound TCM patents related to the treatment of heart failure were extracted from the national patent database ( http://epub.sipo.gov.cn/). Frequency statistics, association rules, complex network, entropy clustering method of TCM Auxiliary Inheritance Platform (V2.5) were used to analyze the data . Results Totally 120 compound TCM patents from September 2003 to November 2017 for the treatment of heart failure were included, involving 383 kinds of Chinese materia medica, and the most common syndrome was qi-deficiency blood-stasis water-stop syndrome (41 times, accounting for 34.17%). The most common Chinese materia medica was Astragali Radix (62 times, accounting for 51.67%). The most common medical combination was Salviae Miltiorrhizae Radix et Rhizoma-Astragali Radix (31 times, accounting for 25.83%). The most common triple combination was Astragali Radix-Poria-Descurainiae Semen Lepidii Semen (16 times, accounting for 13.33%). Confidence-based association rules were “Salviae Miltiorrhizae Radix et Rhizoma, Angelicae Sinensis Radix→Astragali Radix” (0.933), “Codonopsis Radix, Atractylodix Macrocephalae Rhizoma→Astragali Radix” (0.900), “Ginseng Radix et Rhizoma, Descurainiae Semen Lepidii Semen→Poria” (0.889) . The core Chinese materia medica were Astragali Radix, Ginseng Radix et Rhizoma, Salviae Miltiorrhizae Radix et Rhizoma, etc . The new prescriptions were “Cinnamomi Ramulus, Acanthopanacis Cortex, Jujubae Fructus, Aurantii Fructus Immaturus, and Gastrodiae Rhizoma”, “Atractylodix Macrocephalae Rhizoma, Cinnamomi Ramulus, Jujubae Fructus, Angelicae Sinensis Radix, and Paeoniae Radix Rubra”, etc. Conclusion Clinical research and development of new TCM for the treatment of heart failure should give priority to main syndromes, flexibly using medicines for tonifying qi, warming yang, activating blood circulation, dissipating blood stasis, inducing diuresis, reducing phlegm, and nourishing yin, to promote clinical efficacy.
参考文献/References:
[1] 中国心血管病报告编写组.《中国心血管病报告2016》概要[J].中国循环杂志,2017,32(6):521-530.
[2] TANG W H W, HUANG Y. Cardiotonic modulation in heart failure: insights from traditional Chinese medicine[J]. J Am Coll Cardiol, 2013,62(12):1073-1074.
[3] 国家药典委员会.中华人民共和国药典[M].北京:中国医药科技出版社,2015.
相似文献/References:
[1]康旭亮,吕茂平,李洪梅.抗流行性感冒的中药发明专利状况分析[J].中国中医药信息杂志,2012,19(3):1.[doi:10.3969/j.issn.1005-5304.2012.03.001]
[J].zhongguo zhongyiyao xinxi zazhi,2012,19(8):1.[doi:10.3969/j.issn.1005-5304.2012.03.001]
[2]傅俊英,曹燕.美国授权的中药复方专利分析[J].中国中医药信息杂志,2011,18(1):2.[doi:10.3969/j.issn.1005-5304.2011.01.001]
[J].zhongguo zhongyiyao xinxi zazhi,2011,18(8):2.[doi:10.3969/j.issn.1005-5304.2011.01.001]
[3]郭德海,肖诗鹰,刘铜华,等.印度在华中药领域专利分析[J].中国中医药信息杂志,2009,16(2):1.
[J].zhongguo zhongyiyao xinxi zazhi,2009,16(8):1.
[4]赵益业,黄春林,林晓忠.心力衰竭的中西医结合治疗探析[J].中国中医药信息杂志,2007,14(2):81.
[J].zhongguo zhongyiyao xinxi zazhi,2007,14(8):81.
[5]周海峰,赵林颖,鲁宪凯,等.中西医结合治疗慢性收缩性心力衰竭临床观察[J].中国中医药信息杂志,2009,16(10):63.
[J].zhongguo zhongyiyao xinxi zazhi,2009,16(8):63.
[6]郭德海,肖诗鹰,刘铜华,等.日本在华中药领域专利分析[J].中国中医药信息杂志,2008,15(8):1.
[J].zhongguo zhongyiyao xinxi zazhi,2008,15(8):1.
[7]郭德海,肖诗鹰,刘铜华,等.美国在华中药领域专利分析[J].中国中医药信息杂志,2008,15(11):1.
[J].zhongguo zhongyiyao xinxi zazhi,2008,15(8):1.
[8]张宇.新生脉散片治疗射血分数保留的心力衰竭临床观察[J].中国中医药信息杂志,2011,18(5):75.[doi:10.3969/j.issn.1005-5304.2011.05.033]
[J].zhongguo zhongyiyao xinxi zazhi,2011,18(8):75.[doi:10.3969/j.issn.1005-5304.2011.05.033]
[9]吕茂平,康旭亮,王宏,等.单方中药注射剂发明专利申请的现状分析[J].中国中医药信息杂志,2011,18(10):1.[doi:10.3969/j.issn.1005-5304.2011.10.001]
[J].zhongguo zhongyiyao xinxi zazhi,2011,18(8):1.[doi:10.3969/j.issn.1005-5304.2011.10.001]
[10]杨旭杰,肖诗鹰,刘铜华,等.中医药院校加强中药研究生专利教育相关问题研究[J].中国中医药信息杂志,2011,18(11):5.[doi:10.3969/j.issn.1005-5304.2011.11.003]
[J].zhongguo zhongyiyao xinxi zazhi,2011,18(8):5.[doi:10.3969/j.issn.1005-5304.2011.11.003]
备注/Memo
基金项目:国家自然科学基金(81202803);中央公益性科研院所基金科研业务费专项资金资助项目(ZZ0908023);中央本级重大增减支项目(2060302)
更新日期/Last Update:
2018-07-12